March 28, 2018 M&A, Partnerships Mass Spectrometry

Microsaic Systems PLC Agreement with Unimicro Technologies Inc.

28th March 2018 Microsaic Systems PLC (LON:MSYS), the developer of point of need mass spectrometry (“MS”) instruments, has today announced that it has signed an agreement with Unimicro Technologies Inc. (“Unimicro”)(the “Agreement”). The Agreement covers the integration of Microsaic’s compact 4500 MiD® mass spectrometry detector with Unimicro’s Capillary Electrophoresis (“CE”) Platform. Once integrated, the combined product will be... Read more

March 28, 2018 Atomic Spectroscopy

SPECTRO Announces a Major Upgrade of SPECTROTEST Mobile Metal Analyzer

March 28, 2018 SPECTRO Analytical Instruments today announced a major upgrade to its SPECTROTEST arc/spark mobile metal analyzer for applications in the metal producing, processing, and recycling industries. The SPECTROTEST mobile spectrometer delivers precise results without compromise when an exact metal analysis is required, materials are difficult to identify, or there is a large number... Read more

March 27, 2018 M&A, Partnerships

Unchained Labs keeps them coming, acquires rap.ID!

March 27, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, acquired rap.ID today. Rap.ID is a leading provider of systems used for particle identification in biopharmaceutical development and quality control. The company also provides contract services in these areas. This is Unchained Labs’... Read more

March 26, 2018 Clinical Research/Diagn. M&A, Partnerships

Agena and Simceredx Announce Strategic Partnership to Develop and Commercialize Companion Diagnostics in China

26 March 2018 San Diego, Calif., and Nanjing, JiangSu, March 26, 2018 – Agena Bioscience (Agena) and Simcere Diagnostics (Simceredx), the subsidiary of SIMCERE Pharmaceutical Group, announced today the signing of a strategic partnership agreement focusing on expanding the use of Agena’s MassARRAY® System for companion diagnostics and pharmacogenetic testing in China. As a leading pharmaceutical... Read more

March 26, 2018 Life Science Tools Product Launch

Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening

Location: Cambridge 26/03/2018 First-to-market Edit-R CRISPRa arrayed crRNA libraries enable native gene overexpression for high-throughput gain-of-function screening Available as small gene families, bespoke collections, the druggable genome, or human genome-wide collection Cambridge, UK, 26 March 2018: Horizon Discovery (LSE: HZD) (“Horizon” or the “Company”), a global leader in the application of gene editing and gene modulation... Read more

March 25, 2018 Microscopy Product Launch

10x faster lifetime contrast facilitates access to new discoveries

25 March 2018 10x faster lifetime contrast facilitates access to new discoveries Explore molecular interaction at the speed of life with the SP8 FALCON from Leica Microsystems Mannheim, Germany. Leica Microsystems announces the SP8 FALCON, the world’s first truly integrated lifetime contrast microscope. The SP8 FALCON can record lifetime contrast 10x faster than previous solutions.... Read more

March 22, 2018 Process Analytical Instr. Product Launch

IDEX Health & Science Releases QuickStart™ Pressure Sensor

For further information, please contact: Heidi Lechner Tel: +1 707-588-2160 E-mail: hlechner@idexcorp.com March 22, Rohnert Park, CA – IDEX Health & Science, LLC announces the release of their new QuickStart™ Pressure Sensor product line. The sensors monitor and provide accurate, real-time data with digital output, allowing the user (or operator) to predict failure, mitigate risk and... Read more

March 22, 2018 Clinical Research/Diagn. PR/Corporate

Precipio Restructures Capitalization Table

INVESTORS TO CONVERT PREFERRED SHARES AND EXERCISE WARRANTS NEW HAVEN, Conn., March 22, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), in an 8-K issued today announced an agreement with investors in certain 2017 underwritten and registered direct offerings, to convert their preferred shares and exercise a substantial portion of their warrants. The benefit to common stockholders... Read more